I couldn't agree with you any more OTC. The simple fact is to bring a drug/vaccine through clinical trials is so expensive that deep pockets are needed so buyouts are very common in these situations. Moreover this stock has a large short position and what this needs next week is for the buyers to overwhelm the flippers and push the PPS to a point that triggers the shorts to cover. Notice that the L2 has thinned out over the past week. Should be an interesting week. JMO
Oy. Kite was an established NASDAQ traded company with an active pipeline with drugs in clinical trials with real world clinical trial data. Regen is a bankrupt pinky stinky with nothing but IP that isn't proven at all. This comparison is one made on a false premise. No major pharma is going to buy RGBP for its IP.
RGBP is trading on hype and hyperbole. The con is on.